In vitro activity of saperconazole (R66 905) compared with amphotericin B and itraconazole against Aspergillus species.
Twenty isolates of aspergillus were tested against saperconazole and 16 of these against itraconazole and amphotericin B using a macrodilution broth method. For 18 (90%) of 20 isolates tested against saperconazole, MICs were less than or equal to 3.1 mg/l and for 15 (75%) of 20 isolates MFCs were less than or equal to 3.1 mg/l. For 9 (56%) of 16 isolates tested against itraconazole, MICs were less than or equal to 3.1 mg/l, and for 4 (33%) of 12 isolates MFCs were less than or equal to 3.1 mg/l. For all 16 isolates tested against amphotericin B MICs and MFCs were less than or equal to 4.0 mg/l; for 11 of 16 isolates MICs were less than or equal to 2.0 mg/l. Saperconazole appears to be highly active against Aspergillus spp. in vitro, with a bimodal distribution of MICs and MFCs.
Denning
D W
DW
Department of Medicine, Santa Clara Valley Medical Center, San Jose, California 95128.
Hanson
L H
LH
Stevens
D A
DA
D000666:Amphotericin B / Q000494:pharmacology*; D000935:Antifungal Agents / Q000494:pharmacology*; D001231:Aspergillus flavus / Q000187:drug effects* / Q000254:growth & development; D001232:Aspergillus fumigatus / Q000187:drug effects* / Q000254:growth & development; D001393:Azoles / Q000494:pharmacology*; D017964:Itraconazole; D007654:Ketoconazole / Q000031:analogs & derivatives* / Q000494:pharmacology; D013045:Species Specificity
D000935:Antifungal Agents; D001393:Azoles; D017964:Itraconazole; D000666:Amphotericin B; C060571:saperconazole; D007654:Ketoconazole